Our Takotsubo T2 mapping paper in EHJ-CVI received an editorial:
"Reversibility should not be mistaken for benignity."
Drs Luchian and Desai put in one line what took us 110 patients and 763 days of follow-up.
Editorials: peer review you enjoy reading.
@whyCMR@HeartInstitute
It’s a great honor to receive the Zaret-Beller Elite Reviewer Award at #ASNC2026!
I always enjoy reviewing manuscripts for the Journal of Nuclear Cardiology and look forward to supporting the journal’s continued success.
@MyASNC#JNCjournal
On her birthday, the queen of nuclear cardiology takes the stage! 👑🎂
@DorbalaSharmila presents the Phase 3 REVEAL trial evaluating ¹²⁴I-evuzamitide PET/CT for diagnosing cardiac amyloidosis.
New science. Real clinical impact.
@MyASNC#ASNC2026#CardiacAmyloidosis#ThinkPET
❤️🔥Wrapping up #ASNC2026 Las Vegas... Have a safe flight back home everyone ✈️ 🏠
🌟Next stop: Orlando, Fl🔥 #ASNC2027 , Sept 9-12 2027. Save the date📅 @MyASNC
🎙️ Kicking off #ASNC2026 with the Mario Verani Memorial Lecture, presented by @almallahmo
A fascinating journey through the future of Nuclear Cardiology—from SPECT & PET to CCTA, photon-counting CT, new tracers and AI. 🫀🔬
The future is multimodality, precision & patient-centered imaging!
@MyASNC #CVNuc #ThinkPET